Davis Polk

Andrzej O’Leary

Deals
1
Latest
Jan 2026

Firm

Often works with

Deals

US deals dated after 30 September 2026 are still being collected.

Columns
Deals Andrzej O’Leary was named on, most recent first
Jan 2026 AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 AbelZetaAstraZenecaAsset saleLegal adviser to AbelZeta (target)Announced630.0Biotech+2AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031

Deals where Andrzej O’Leary is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.